Dan Mangan is a reporter covering health care and other issues for CNBC.com.
Mangan has been a journalist for more than 20 years, most recently as a general assignment/rewrite reporter at the New York Post. In his more than dozen years at The Post, Mangan routinely covered major stories, including the 9/11 terror attacks, the Bernard Madoff Ponzi scheme, the 2008 financial meltdown and a slew of juicy Gotham scandals du jour, among them the personal tribulations of Yankee slugger Alex Rodriguez.
Prior to that, Mangan began his career in his native Connecticut, writing obituaries for The Hour of Norwalk, before moving on to cover business, government and the court systems at The Hour, the Fairfield County Business Journal and The Advocate of Stamford.
Congress demanded more documents about how much Mylan actually makes on EpiPen anti-allergy devices, which have skyrocketed in price.
Harken Health charges customers nothing out of pocket for primary care visits to the insurer's clinics, but it bled cash.
Older people are more at risk for the flu, but officials say everyone older than 6 months should get vaccinated.
A report also found similar reductions in the uninsured rate in urban and rural areas under Obamacare.
Two-thirds of Americans want an independent body to oversee prescription drug pricing.
Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid.
Young adults continue to have high rates of uninsurance despite gains made under Obamacare.
A restatement by Mylan of EpiPen profit figures is just the latest problem for the drugmaker.
Media pundits were underwhelmed, at best, by Donald Trump's debate performance against Hillary Clinton.
Donald Trump yesterday set off an explosion on Twitter at the first presidential debate not by some outrageous remark, but by a bad case of the sniffles.